Articles

Selected category: Other

CNBC is running their annual Million Dollar Stock portfolio contest this year. You can trade stocks or currencies and win weekly prizes or a pool of one million dollars if you finish in the top 6.

Read →

A new tool from HeatMap.com combines rental and housing sales data to provide an indicator on whether it makes sense to rent or to buy.

Read →

Want to make big money? Become a CEO and keel over.

Read →

Nikesh Arora believes that eventually all smaller Blogs and content providers will get squeezed out and the survivors will start to charge. Will you pay?

Read →

Just watching Matt Simmons in TV. He published a book 3 years ago when oil was at $30 saying that oil is going much higher. Hiss views on peak oil are not completely absurd.

Read →

With oil at $130 a barrel, here is the most sensible idea. It is also a bitter pill to swallow.

Read →

Microsoft just launched a new cash back program in an attempt to promote their Live search engine and steal market share from Google. Will it work and is it worth it? Here's what I found out on my quick shopping spree.

Read →

This is a discussion on the future direction of the Federal Funds rate, using the Fed Funds Rate Predictor (produced by the Cleveland Fed) as a starter.

Read →

The Euro is going down.

Read →

According to an unscientific poll done by NetBanker, 13% of users said they would be interested in doing their banking from within Facebook. Would you?

Read →

Techcrunch interviewed Citi Analyst Mark Mahaney On Yahoo/Microsoft/Google. It's a good interview although I tend to disagree with his conclusions.

Read →

Microsoft's numbers indicate very clearly that that technology growth by and large is anemic. There are only four stocks that anyone should be looking at - here they are.

Read →

Think the mutual fund you own is a special investment. Think again. Most financial companies package and sell mutual funds like a supermarket sells soap. Bulk it up and ship it out.

Read →

CVTX just sold half of the rights to their new stress testing drug for a price that shows just how undervalued their stock is.

Read →

Merck and Schering are way up from their recent lows- and AZN is off its recent highs. There is more money to be made here, but making the same trades I recommended last week.

Read →